What Do the US Midterms Mean for Medtech?

Update: 2022-12-01

Description

Key retirements, important changes in leadership, and some surprising new faces. Now that the dust has almost settled, leaving just one Senate run-off and several House seats still to be settled, what does the election’s outcome mean for the medical device industry, both in terms of prospects for the rest of this year and for the new Congress in 2023? MDMA’s Mark Leahey and Advamed’s Greg Crist offer their perspectives on this podcast with Market Pathways editors Stephen Levin and David Filmore.

Comments

In Channel

Ep. 33: What Does it Mean to be a Reimbursement Professional?

2025-10-1632:37

Ep. 32: The Tariff Challenge, Policy Optimism, and The MedTech Conference With Scott Whitaker

2025-09-2245:37

EP 31: Haven’t We Heard This Song Before? Major EU Regulatory Changes on the Horizon

2025-07-2444:20

BTIG Weighs In on Whether Trump Policies Can Dent MedTech’s Healthy Run

2025-03-0729:54

Pioneering the Use of Real-World Evidence in Medtech: A Discussion with J&J’s Paul Coplan

2024-08-0101:06:17

FDA Inspections Getting Prepped and Avoiding Pitfalls

2024-05-2531:44

A VC’s View of the Reimbursement Evolution: An Interview with Mike Carusi

2024-03-2749:25

Reimbursement for Breakthrough Devices Still Lags—Need for TCET: An Interview with Josh Makower

2023-09-1956:25

Ep. 25: Medtech in China: An Island of Relative Calm in a Sea of Volatility

2023-08-1035:55

An Interview With Kevin Fu, The First Device Cyber Czar

2023-06-2736:21

The Real World Impact of MDR: How CEOs and Investors are Adapting

2023-05-1941:37

Medtech Law & Policy - Clearing Up the Confusion on MDR: Where Do We Go From Here?